Immunotech Biopharm Ltd (HK:6978)
:6978
Want to see HK:6978 full AI Analyst Report?
6978 Stock Chart & Stats
HK$2.68
-HK$0.01(-0.43%)
At close: 4:00 PM EST
HK$2.68
-HK$0.01(-0.43%)
Day’s Range― - ―
52-Week RangeHK$0.79 - HK$5.40
Previous CloseN/A
Volume50.00K
Average Volume (3M)1.34M
Market Cap
HK$518.70M
Enterprise ValueHK$760.46M
Total Cash (Recent Filing)HK$154.63M
Total Debt (Recent Filing)HK$440.26M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding617,500,800
10 Day Avg. Volume1,608,107
30 Day Avg. Volume1,338,788
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-103.70
Price to Sales (P/S)0.00
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
DeleveragingThe sharp reduction in reported total debt from 784.0M (2023) to 103.7M (2025) materially lowers gross leverage. Sustained deleveraging reduces refinancing and interest burden, improving financing optionality and giving management structural flexibility for R&D, partnerships or contingency funding.
Improving Cash BurnSequential improvement in free cash flow (‑111.9M in 2025 vs. ‑186.2M in 2023) signals effective cost containment and operational tightening. A durable downtrend in burn extends runway, lowers near‑term external funding needs and supports longer‑term execution of development milestones if sustained.
Sizable Asset BaseA 603.2M asset base provides a tangible balance‑sheet cushion that can support ongoing R&D spending, serve as collateral for financing, or be monetized/licensed. Such assets preserve operational optionality and underwrite strategic choices over the medium term if capital access is managed prudently.
Bears Say
No Reported RevenueA complete absence of reported revenue across 2020–2025 defines a pre‑commercial profile with no proven cash‑generating product. Long‑term viability therefore hinges on successful approvals, partnerships or licensing; until then the company lacks operational cash flow and faces high execution and commercialization risk.
Negative Equity / Solvency RiskThe shift to negative shareholders' equity in 2024–2025 is a structural solvency concern. Negative equity limits borrowing capacity, can tighten covenant and pricing on new capital, and may force dilutive raises or restructuring. Persistent negative equity undermines long‑term financial flexibility and resilience.
Sustained Operating Cash DeficitsConsistent negative operating cash flow indicates the business is not self‑funding and relies on external capital. Even with burn improvement, recurring annual deficits strain liquidity, constrain strategic choices and raise the probability of dilutive financing or partnerships to maintain clinical and development programs over the medium term.
Immunotech Biopharm Ltd News
6978 FAQ
What was Immunotech Biopharm Ltd’s price range in the past 12 months?
Immunotech Biopharm Ltd lowest stock price was HK$0.79 and its highest was HK$5.40 in the past 12 months.
What is Immunotech Biopharm Ltd’s market cap?
Immunotech Biopharm Ltd’s market cap is HK$518.70M.
When is Immunotech Biopharm Ltd’s upcoming earnings report date?
Immunotech Biopharm Ltd’s upcoming earnings report date is Aug 21, 2026 which is in 92 days.
How were Immunotech Biopharm Ltd’s earnings last quarter?
Immunotech Biopharm Ltd released its earnings results on Mar 20, 2026. The company reported -HK$0.208 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.208.
Is Immunotech Biopharm Ltd overvalued?
According to Wall Street analysts Immunotech Biopharm Ltd’s price is currently Overvalued.
Does Immunotech Biopharm Ltd pay dividends?
Immunotech Biopharm Ltd does not currently pay dividends.
What is Immunotech Biopharm Ltd’s EPS estimate?
Immunotech Biopharm Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Biopharm Ltd have?
Immunotech Biopharm Ltd has 617,500,800 shares outstanding.
What happened to Immunotech Biopharm Ltd’s price movement after its last earnings report?
Immunotech Biopharm Ltd reported an EPS of -HK$0.208 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.959%.
Which hedge fund is a major shareholder of Immunotech Biopharm Ltd?
Currently, no hedge funds are holding shares in HK:6978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunotech Biopharm Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.94%
12-Months-Change
Fundamentals
Return on Equity
293.08%
Trailing 12-Months
Asset Growth
11.88%
Trailing 12-Months
Company Description
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
SinoMab Bioscience Ltd.
―
Zhaoke Ophthalmology Ltd.
―
Options Prices
Currently, No data available
---